Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation

NCT ID: NCT06243354

Last Updated: 2026-01-29

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 257 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-02-04
• Study Completion Date: 2026-12-31

Brief Summary

This is a multicenter, open-label phase 1/2 study consisting of two parts: dose escalation phase and dose expansion phase. The objective of the dose escalation phase is to evaluate the safety, tolerability and pharmacokinetics of HYP-2090PTSA in patients with advanced solid tumors harboring KRAS mutation and to determine the RP2D. In the dose expansion phase, preliminary efficacy and safety at the RP2D will be further explored in patients with specific cancer harboring KRAS p.G12C mutation.

Conditions

Safety; Tolerability; Efficacy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Test product-HYP-2090PTSA

Group Type: EXPERIMENTAL

Test product: HYP-2090PTSA

Intervention Type: DRUG

Dosage form: Capsule. Strength: 2.5 mg, 5 mg and 10mg. Method of administration: Take orally on an empty stomach. Do not chew. Swallow the product with warm water.

Dose Escalation Phase PK Lead-in Period (C0D1 only): Take once (QD dosing regimen only). Starting from C1D1, and in the Dose Expansion part, subjects will take the protocol-specified dose of HYP-2090PTSA orally in the morning on an empty stomach and one hour before the evening meal (evening dosing applies to BID regimen only), administered once to twice daily or two to three times per week. The administration dosages are: QD (once daily); BID (twice daily); TIW (on Days 1, 3, and 5 of each week); BIW (on Days 1 and 4 of each week).

Avoid drinking water as much as possible within 1 hour before and after dosing (except for the water taken with the medication).

Do not re-administer the dose if vomiting occurs after drug intake.

Interventions

Test product: HYP-2090PTSA

Dosage form: Capsule. Strength: 2.5 mg, 5 mg and 10mg. Method of administration: Take orally on an empty stomach. Do not chew. Swallow the product with warm water.

Dose Escalation Phase PK Lead-in Period (C0D1 only): Take once (QD dosing regimen only). Starting from C1D1, and in the Dose Expansion part, subjects will take the protocol-specified dose of HYP-2090PTSA orally in the morning on an empty stomach and one hour before the evening meal (evening dosing applies to BID regimen only), administered once to twice daily or two to three times per week. The administration dosages are: QD (once daily); BID (twice daily); TIW (on Days 1, 3, and 5 of each week); BIW (on Days 1 and 4 of each week).

Avoid drinking water as much as possible within 1 hour before and after dosing (except for the water taken with the medication).

Do not re-administer the dose if vomiting occurs after drug intake.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• A written informed consent should be signed by a subject or his/her legal representative before any study-related procedures are performed;
• 18 Years and older;
• Subjects with histologically or cytologically confirmed locally advanced or metastatic advanced solid tumors;
• Subjects must have at least one measurable lesion as defined by RECIST v1.1;
• Eastern Cooperative Oncology Group(ECOG) performance status 0-1;
• Expected survival ≥ 3 months;
• Patients are willing to use a highly effective method of birth control during the study, and for at least 180 days after the last dose of study medication.

Exclusion Criteria

• Patients who have received major surgical or interventional treatment within 4 weeks prior to the first dose, with the exception of tumor biopsy, puncture, etc. Patients who have received anti-tumor therapy (radiotherapy, immunologic therapy or biological therapy) within 4 weeks, prior to the first dose, or received small molecular targeted therapy, chemotherapy within 2 weeks, or received palliative radiotherapy for bone metastases within 2 weeks, or received nitrosoureas or mitomycin C within 6 weeks;
• Patients who have received live vaccines within 4 weeks prior to the first dose;
• Patients who have previously participated in clinical trials of other drugs within 4 weeks before the first dose;
• Patients with a history of central nervous system disease within 12 months prior to enrollment, such as seizures, cerebral vascular embolism/hemorrhage, paralysis, aphasia, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychiatric disease, or any autoimmune disease with involvement of the central nervous system;
• Presence of severe pulmonary diseases such as pulmonary embolism, interstitial lung disease at screening;
• Patients who have previously received allogeneic tissue/solid organ transplantation;
• Patients with active infection;
• Patients who are positive for human immunodeficiency virus (HIV) (HIV1/2 antibody), positive treponema pallidum antibody (positive treponema pallidum antibody is required to undergo a confirmatory test, and those with negative confirmatory test can be enrolled), active chronic hepatitis B (HBsAg positive and HBV DNA > 500 IU/mL) or active hepatitis C (HCV antibody positive and HCV-RNA > lower limit of detection by the research center);
• Female subjects who are lactating or have a positive blood/urine pregnancy result during the screening period;
• Any other condition of the subject (e.g., mental, geographical, or medical condition) that does not allow him or her to comply with the study and follow-up procedures, or other conditions that, in the judgment of the investigator, the subject is not suitable for inclusion in this study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sichuan Huiyu Pharmaceutical Co., Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Fujian Provincial Cancer Hospital

Fuzhou, Fujian, China

Site Status: RECRUITING

Hunan Provincial Cancer Hospital

Changsha, Hunan, China

Site Status: NOT_YET_RECRUITING

The first Hospital of China Medical University

Shenyang, Liaoning, China

Site Status: NOT_YET_RECRUITING

Shandong Provincial Cancer Hospital

Jinan, Shandong, China

Site Status: NOT_YET_RECRUITING

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

West China Hospital of Sichuan University

Chengdu, Sichuan, China

Site Status: RECRUITING

Countries

China

Central Contacts

Kai Chang

Role: CONTACT

kai.chang4086@huiyupharma.com

+86-028-86021875

Facility Contacts

Yigui Chen, Professor

Role: primary

Lin Wu, Professor

Role: primary

Mingfang Zhao, Professor

Role: primary

Qi Dang, Professor

Role: primary

Caicun Zhou, Professor

Role: primary

Meng Qiu, Professor

Role: primary

Other Identifiers

HY0002-101

Identifier Type: -

Identifier Source: org_study_id